Society of gynecologic oncology statement on risk assessment for inherited gynecologic cancer predispositions

Gynecologic Oncology

Volumn 136, Issue 1, 2015, Pages 3-7

  Lancaster, Johnathan M ^a   Powell, C Bethan ^b,c   Chen, Lee May ^c   Richardson, Debra L ^d  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b KAISER PERMANENTE MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

BRCA1; BRCA2; Cowden syndrome; Genetic testing; Hereditary cancer; Lynch syndrome

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; MISMATCH REPAIR PROTEIN PMS2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE LKB1; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; PROTEIN P53;

ARTICLE; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CANCER SUSCEPTIBILITY; CHEMOPROPHYLAXIS; COLORECTAL CANCER; DISEASE PREDISPOSITION; ENDOMETRIUM CANCER; FAMILIAL CANCER; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC SCREENING; GERMLINE MUTATION; GYNECOLOGIC CANCER; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; INFORMED CONSENT; MEDICAL SOCIETY; MENTAL STRESS; MISMATCH REPAIR; MORBIDITY; OVARY CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; RISK ASSESSMENT; FEMALE; GENETIC PREDISPOSITION; GENETICS; GENITAL NEOPLASMS, FEMALE; PRACTICE GUIDELINE; PROCEDURES; STANDARDS;

FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENITAL NEOPLASMS, FEMALE; GERM-LINE MUTATION; HUMANS; RISK ASSESSMENT;

EID: 84925229366     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.09.009     Document Type: Article

References (61)

1. Garber JE, Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol 2005;23(2):276-92.
2. Karlan BY, Berchuck A, Mutch D. The role of genetic testing for cancer susceptibility in gynecologic practice. Obstet Gynecol 2007;110(1):155-67.
3. Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med 2003;348(23):2339-47.
4. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003;348(10):919-32.
5. Miki Y, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266(5182):66-71.
6. Wooster R, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378(6559):789-92.
7. Lancaster JM, et al. BRCA2 mutations in primary breast and ovarian cancers. Nat Genet 1996;13(2):238-40.
8. Fishel R, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993;75(5):1027-38.
9. Leach FS, et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993;75(6):1215-25.
10. Bronner CE, et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 1994;368(6468):258-61.
11. Papadopoulos N, et al. Mutation of a mutL homolog in hereditary colon cancer. Science 1994;263(5153):1625-9.
12. Walsh T, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A 2011;108(44):18032-7.
13. Ford D, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998;62(3):676-89.
14. Antoniou A, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72(5):1117-30.
15. King MC, Marks JH, Mandell JB, New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302(5645):643-6.
16. Barrow E, Hill J, Evans DG. Cancer risk in Lynch syndrome. Fam Cancer 2013;12(2):229-40.
17. Vasen HF, et al. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol 2001;19(20):4074-80.
18. Hendriks YM, et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology 2004;127(1):17-25.
19. Plaschke J, et al. Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium. J Clin Oncol 2004;22(22):4486-94.
20. Barrow E, et al. Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations. Clin Genet 2008;74(3):233-42.
21. Barrow E, et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet 2009;75(2):141-9.
22. Ramsoekh D, et al. Cancer risk in MLH1, MSH2 and MSH6 mutation carriers; different risk profiles may influence clinical management. Hered Cancer Clin Pract 2009;7(1):17.
23. Stoffel E, et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology 2009;137(5):1621-7.
24. Baglietto L, et al. Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst 2010;102(3):193-201.
25. Bonadona V, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 2011;305(22):2304-10.
26. Therkildsen C, et al. Cancer risks and immunohistochemical profiles linked to the Danish MLH1 Lynch syndrome founder mutation. Fam Cancer 2012;11(4):579-85.
27. Senter L, et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 2008;135(2):419-28.
28. Pilarski R. Cowden syndrome: a critical review of the clinical literature. J Genet Couns 2009;18(1):13-27.
29. Riegert-Johnson D, et al. Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients. Hered Cancer Clin Pract 2010;8(1):6.
30. Tan M, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 2012;18(2):400-7.
31. Bubien V, et al. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet 2013;50(4):255-63.
32. Gonzalez KD, et al. Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 2009;27(8):1250-6.
33. Hemminki A, et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998;391(6663):184-7 [34].
34. Loveday C, et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet 2011;43:879-82.
35. Loveday C, et al. Germline RAD51C mutations confer susceptibility to ovarian cancer. Nat Genet 2012;44:475-6.
36. Rafnar T, et al. Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet 2011;43:1104-7.
37. Casadei S, et al. Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Res 2011;71(6):2222-9.
38. Walsh T, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci 2011;108(44):18032-7.
39. Rio Frio T, et al. DICER1 mutations in familial multinodular goiter with and without ovarian Sertoli-Leydig cell tumors. JAMA 2011;305(1):68-77.
40. Sabbaghian N, et al. Germ-line deletion in DICER1 revealed by a novel MLPA assay using synthetic oligonucleotides. Eur J Hum Genet 2014;22(4):564-7.
41. Kupryjañczyk J, et al. Ovarian small cell carcinoma of hypercalcemic type - evidence of germline origin and SMARCA4 gene inactivation. a pilot study. Pol J Pathol 2013;64(4):238-46.
42. Jelinic P, et al. Recurrent SMARCA4 mutations in small cell carcinoma of the ovary. Nat Genet 2014;46(5):424-6.
43. Witkowski L, et al. Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. Nat Genet 2014;46(5):438-43.
44. Ramos P, et al. Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. Nat Genet 2014;46(5):427-9.
45. Kriege M, et al. Efficacy of MRI and mammography for breast cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004;351(5):427-37.
46. Warner E, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004;292(11):1317-25.
47. Jarvinen HJ, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000;118(5):829-34.
48. Phillips KA, et al. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2013;31(25):3091-9.
49. Gronwald J, et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update. Int J Cancer 2006;118(9):2281-4.
50. Available from: http://files.shareholder.com/downloads/MYGN/2784875405x0x661835/b6aec217-2edd-4afc-be8e-d0a36414ce91/AnalystDay-Presentation-FINAL.pdf.
51. Domchek SM, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010;304(9):967-75.
52. Fong PC, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010;28(15):2512-9.
53. Couch FJ, et al. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet 2013;9(3): e1003212.
54. Bellcross CA, Page PZ, Meaney-Delman D. Direct-to-consumer personal genome testing and cancer risk prediction. Cancer J 2012;18(4):293-302.
55. Weitzel JN, et al. Limited family structure and BRCA gene mutation status in single cases of breast cancer. JAMA 2007;297(23):2587-95.
56. Kauff ND, Offit K. Modeling genetic risk of breast cancer. JAMA 2007;297(23):2637-9.
57. Kramer JL, Velazquez IA, Chen BE, Rosenberg PS, Struewing JP, Greene MH. Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. J Clin Oncol 2005;23(34):8629-35.
58. Lynch Syndrome. Practice Bulletin No. 147. Society of Obstetricians and Gynecologists. Obstet Gynecol 2014;124:1042-54.
59. Schwartz MD, et al. Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer. J Clin Oncol 2014;32(7):618-26.
60. Hall M, Rich SS. Laws restricting health insurers' use of genetic information: impact on genetic discrimination. Am J Hum Genet 2000;66:293-307.
61. Armstrong K, et al. Life insurance and breast cancer risk assessment: adverse selection, genetic testing decisions, and discrimination. Am J Med Genet A 2003;120A(3):359-64.